Arcadia Biosciences Files Prospectus Pursuant To Which Selling Stockholders May Offer Up To 11.92M Shares Of Common Stock For Resale

Arcadia Biosciences shares are trading higher after the company reported a year-over-year increase in its Q2 EPS results.

Arcadia Biosciences Q2 EPS $(2.09) Up From $(3.26) YoY, Sales $1.443M Down From $1.455M YoY

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(2.09) per share. This is a 35.89 percent increase over losses of $(3.26) per share from the same period last year. The company reported $1.443 million in

8-K filing — Arcadia Biosciences, Inc. (RKDA)

Filed: 2026-08-13 AccNo: 0001193125-26-349180 Size: 681 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits